Profile picture

Doctor Alexander Tindale

Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)
Membership: ESC Professional Member EAPCI Member
Follow
Biography
Dr Tindale is an interventional cardiology consultant based at Harefield Hospital and an honorary senior clinical lecturer at the National Heart and Lung Institute, Imperial College London. His research focusses on the application of quantitative methods to the optimisation of haemodynamics in cardiac critical care, ranging from pacemaker optimisation to the identification and treatment of patients with cardiogenic shock. He studied Natural Sciences at the University of Cambridge (Emmanuel College) before completing both his MBBS and PhD at Imperial College London. In addition, he has a degree in Business & Finance from the Judge Business School, University of Cambridge. Away from medicine, his research interests include improving his golf handicap and scoring more runs on the cricket field.
Logo ESC

Contributor content

Validation of the BALLAR score for predicting 30-day mortality in patients requiring Impella monotherapy
Presentation
Validation of the BALLAR score for predicting 30-day mortality in patients requiring Impella monotherapy
The BE-ALIVE score: predicting 30-day mortality in patients presenting with acute coronary syndromes and cardiogenic shock
Presentation
The BE-ALIVE score: predicting 30-day mortality in patients presenting with acute coronary syndromes and cardiogenic shock
Lowest peak central venous pressure correlates with highest invasive arterial blood pressure as a method for optimising AV delay in post-surgical temporary pacing
Presentation
Lowest peak central venous pressure correlates with highest invasive arterial blood pressure as a method for optimising AV delay in post-surgical temporary pacing
Creation and validation of a biochemical scoring system and smartphone application to predict 30 day mortality in patients requiring left-sided Impella monotherapy
Presentation
Creation and validation of a biochemical scoring system and smartphone application to predict 30 day mortality in patients requiring left-sided Impella monotherapy

ESC 365 is supported by